Metastatic lung adenocarcinoma with BRCA2 mutation and longstanding disease control on olaparib, developing triple negative breast adenocarcinoma with additional BRCA2 reversion mutation: a case report

Peer Review reports

Original Submission
26 Jun 2023	Submitted	Original manuscript
7 Jul 2023	Reviewed	Reviewer Report - Ali Fanoodi
26 Jul 2023	Reviewed	Reviewer Report - Shanila Ahmed
27 Jul 2023	Reviewed	Reviewer Report - Mirette Hanna
15 Aug 2023	Author responded	Author comments - Auro del Giglio
Resubmission - Version 2
15 Aug 2023	Submitted	Manuscript version 2
Publishing
22 Aug 2023	Editorially accepted
25 Sep 2023	Article published	10.1186/s13256-023-04139-x

Back to article page